Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q92997
UPID:
DVL3_HUMAN
Alternative names:
DSH homolog 3
Alternative UPACC:
Q92997; B4E3E5; D3DNT0; O14642; Q13531; Q8N5E9; Q92607
Background:
Segment polarity protein dishevelled homolog DVL-3, also known as DSH homolog 3, plays a pivotal role in the Wnt signaling pathway. This pathway is crucial for cell fate determination, cell migration, and embryonic development. The protein's involvement in multiple Wnt genes' signal transduction underscores its significance in these biological processes.
Therapeutic significance:
DVL-3 is linked to Robinow syndrome, autosomal dominant 3, a rare skeletal dysplasia syndrome. This connection highlights the protein's potential as a target for therapeutic intervention in treating skeletal and developmental anomalies associated with this condition.